Literature DB >> 24650704

Using 'biased-privileged' scaffolds to identify lysine methyltransferase inhibitors.

Sudhir Kashyap1, Joel Sandler2, Ulf Peters2, Eduardo J Martinez2, Tarun M Kapoor3.   

Abstract

Methylation of histones by lysine methyltransferases (KMTases) plays important roles in regulating chromatin function. It is also now clear that improper KMTases activity is linked to human diseases, such as cancer. We report an approach that employs drug-like 'privileged' scaffolds biased with motifs present in S-adenosyl methionine, the cofactor used by KMTases, to efficiently generate inhibitors for Set7, a biochemically well-characterized KMTase. Setin-1, the most potent inhibitor of Set7 we have developed also inhibits the KMTase G9a. Together these data suggest that these inhibitors should provide good starting points to generate useful probes for KMTase biology and guide the design of KMTase inhibitors with drug-like properties.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inhibitors; KMTases; Post-translational modifications; SET7; ‘Privileged’ scaffolds

Mesh:

Substances:

Year:  2014        PMID: 24650704      PMCID: PMC4038709          DOI: 10.1016/j.bmc.2014.02.024

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  31 in total

Review 1.  Errors in erasure: links between histone lysine methylation removal and disease.

Authors:  Elizabeth M Duncan; C David Allis
Journal:  Prog Drug Res       Date:  2011

2.  Development of novel bisubstrate-type inhibitors of histone methyltransferase SET7/9.

Authors:  Shuichi Mori; Kenta Iwase; Naoko Iwanami; Yujiro Tanaka; Hiroyuki Kagechika; Tomoya Hirano
Journal:  Bioorg Med Chem       Date:  2010-10-14       Impact factor: 3.641

3.  A myosin V inhibitor based on privileged chemical scaffolds.

Authors:  Kabirul Islam; Harvey F Chin; Adrian O Olivares; Lauren P Saunders; Enrique M De La Cruz; Tarun M Kapoor
Journal:  Angew Chem Int Ed Engl       Date:  2010-11-02       Impact factor: 15.336

4.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.

Authors:  Stefan Kubicek; Roderick J O'Sullivan; E Michael August; Eugene R Hickey; Qiang Zhang; Miguel L Teodoro; Stephen Rea; Karl Mechtler; Jennifer A Kowalski; Carol Ann Homon; Terence A Kelly; Thomas Jenuwein
Journal:  Mol Cell       Date:  2007-02-09       Impact factor: 17.970

Review 5.  Role of histone modifications in defining chromatin structure and function.

Authors:  Kathy A Gelato; Wolfgang Fischle
Journal:  Biol Chem       Date:  2008-04       Impact factor: 3.915

6.  Efficient elimination of nonstoichiometric enzyme inhibitors from HTS hit lists.

Authors:  Michael Habig; Anke Blechschmidt; Sigmar Dressler; Barbara Hess; Viral Patel; Andreas Billich; Christian Ostermeier; David Beer; Martin Klumpp
Journal:  J Biomol Screen       Date:  2009-05-21

7.  Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase.

Authors:  Jiaquan Wu; Tony Cheung; Christie Grande; Andrew D Ferguson; Xiahui Zhu; Kelly Theriault; Erin Code; Cynthia Birr; Nick Keen; Huawei Chen
Journal:  Biochemistry       Date:  2011-06-29       Impact factor: 3.162

Review 8.  Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark.

Authors:  Alexander J Ruthenburg; C David Allis; Joanna Wysocka
Journal:  Mol Cell       Date:  2007-01-12       Impact factor: 17.970

9.  Kinetic manifestation of processivity during multiple methylations catalyzed by SET domain protein methyltransferases.

Authors:  Lynnette M A Dirk; E Megan Flynn; Kevin Dietzel; Jean-François Couture; Raymond C Trievel; Robert L Houtz
Journal:  Biochemistry       Date:  2007-03-06       Impact factor: 3.162

10.  Activation and inhibition of DNA methyltransferases by S-adenosyl-L-homocysteine analogues.

Authors:  Ritesh Kumar; Richa Srivastava; Ramendra Kumar Singh; Avadhesha Surolia; Desirazu N Rao
Journal:  Bioorg Med Chem       Date:  2007-12-03       Impact factor: 3.641

View more
  2 in total

1.  Revealing inhibition difference between PFI-2 enantiomers against SETD7 by molecular dynamics simulations, binding free energy calculations and unbinding pathway analysis.

Authors:  Yuzhen Niu; Danfeng Shi; Lanlan Li; Jingyun Guo; Huanxiang Liu; Xiaojun Yao
Journal:  Sci Rep       Date:  2017-04-18       Impact factor: 4.379

2.  Homocysteine-targeting compounds as a new treatment strategy for diabetic wounds via inhibition of the histone methyltransferase SET7/9.

Authors:  Guodong Li; Dan Li; Chun Wu; Shengnan Li; Feng Chen; Peng Li; Chung-Nga Ko; Wanhe Wang; Simon Ming-Yuen Lee; Ligen Lin; Dik-Lung Ma; Chung-Hang Leung
Journal:  Exp Mol Med       Date:  2022-07-20       Impact factor: 12.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.